Bladder Cancer Weekly

December 30, 2024

Videos

Peer-to-Peer Clinical Conversations

Addressing Cognitive Decline in Bladder Cancer Patients Through Prehab and Rehab - Sarah Psutka

Sarah Psutka

Zachary Klaassen speaks with Sarah Psutka about cognitive resilience in bladder cancer care.

View

SWOG Trial On Standard vs Extended Lymphadenectomy in Muscle Invasive Bladder Cancer - Seth Lerner

Seth Lerner

Seth Lerner discusses the SWOG study on standard versus extended lymphadenectomy for muscle-invasive bladder cancer published October 2024 in the New England Journal of Medicine.

View

Beyond the Abstracts

Histopathological, Molecular and Clinical Profiling of Lymphoepithelioma-Like Carcinoma of the Bladder (LELC-B) - Beyond the Abstract

Immunotherapy Plus Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Urothelial Cancer: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials - Beyond the Abstract

Conference Coverage

SUO 2024: Keynote Lecture: Precision in Urothelial Carcinoma – FGFR

SUO 2024: Heterogeneity of Intermediate Risk NMIBC

SUO 2024: Emerging Perioperative Systemic Therapy

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Impact of BMI Category on Recurrence and Progression of Nonmuscle Invasive Bladder Cancer Prognosis.

The Financial Burden of Localized and Metastatic Bladder Cancer.

Oncological outcomes and prognostic implications of T1 histo-anatomic substaging in the management of high-Grade non-muscle invasive bladder cancer: results from a large single centre series.

Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI.

A novel smartphone application for bladder cancer management (BCM App): Design, development, and usability evaluation.

PLAP expression is linked to invasive tumor growth in urothelial carcinoma of the bladder.

Exploring the Immunoresponse in Bladder Cancer Immunotherapy.

Transformative or transitional? Deciphering the role of NIAGARA in shaping future practice.

Evaluation of Gemcitabine and Carboplatin Dosing in Patients With Cisplatin-Ineligible Metastatic Urothelial Carcinoma.

Reflections on the AMBASSADOR trial: The role of adjuvant pembrolizumab in muscle-invasive urothelial carcinoma.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Bladder Cancer Weekly

Bladder Cancer

Login